跳至主要内容
临床试验/NL-OMON39306
NL-OMON39306招募中不适用

An Exploratory Observational, Single-Centre Study in Patients with Disabling Chronic Obstructive Pulmonary Disease to Identify Biomarkers for *Systemic Disease*, Co-Morbidities, Increased Health Care Costs and Poor Prognosis. (CIROCO). - CIROCO study

Astra Zeneca0 个研究点目标入组 310 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
310

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Severe COPD: 1: referred to the CIRO in Horn for a lung rehabiliation program 2: agreeing to participate and signed informed consent, 3: age 40 - 80 year, 4: lungfunction (post-bronchodilator FEV1) below 80% of predicted, 5: ratio FEV1 / FVC (post-bronchodilator) below 0.70, 6: current or ex-smoker with at least 10 pack-years
  • Healthy control subjects: 1: agreeing yto participate and signed informed consent , 2; age 40 - 80 years, 3: healthy, 4: lungfunction (post-bronchodilator FEV1) above 85% of predicted, 5: Ratio FEV1 / FVC (post bronchodilator) above 85% of predicted, 6: non-smoker or ex-smoker with less than 10 pack-years.
  • Mild COPD: 1: agreeing to particpate and signed informed consent , 2: COPD diagnosis confirmed in the BOLD project.

排除标准

  • All participants: history of asthma, other lung disease, severe cardiac disease, rheumatoid arthritis, bone disease, other concomitant disease, malignancy, pregnancy, physical handicap making walking impossible, alcohol or drug abuse, recent blood donation.

研究者

发起方
Astra Zeneca

相似试验